When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
52 months after a suggestive brain scan indicated a strong possibility of CTE in a former NFL player, the diagnosis has been confirmed by autopsy following the ex-players…
Primary care physicians (PCPs) remain the gatekeepers of medicine and are on the front-lines of diagnosis, evaluation, and treatment of a plethora of conditions. Adult attention-deficit / hyperactivity…
Researchers from University College London (UCL) are working on a project with the lofty goal of analyzing the entirety of a brain’s neuronal activity in real time. Most…
The AMA is augmenting its support of the Centers for Medicare and Medicaid Services’ (CMS) proposals for the second year of the Quality Payment Program (QPP) with a…
Each month we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
